Business · 18/05/2012
FDA Clears Vasopressin Tannate Injection for Approval via Abbreviated New Drug Applications
The FDA has determined that vasopressin tannate injection, 5 pressor units/mL, was not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of abbreviated new drug applications.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →